Media

C4X Discovery to highlight conformational insights at two conferences in September

Manchester, UK, August 28 2013 – C4X Discovery (C4XD; formerly Conformetrix), a leader in conformational drug discovery and design, is highlighting at two conferences in September the potential of its dynamic NMR technology to provide significant conformational insights. Following on from the company's recent announcement that it has solved the solution-structure of a Class B GPCR ligand in one week, the presentations will provide further insight into how the 4D structures generated by the company's MolGyrate technology can be used in drug design.

C4X Discovery (C4XD; formerly Conformetrix), a leader in conformational drug discovery and design, is highlighting at two conferences in September the potential of its dynamic NMR technology to provide significant conformational insights. Following on from the company's recent announcement that it has solved the solution-structure of a Class B GPCR ligand in one week, the presentations will provide further insight into how the 4D structures generated by the company's MolGyrate technology can be used in drug design.

At the 17th RSC/SCI Medicinal Chemistry Symposium on September 8-11 in Cambridge, UK, the company will present a poster on 'Free Ligand Conformational Populations in Solution - A Powerful Drug Discovery Tool'. On September 25th at the Small Molecule NMR Conference in Santiago de Compostela, Spain, C4X Discovery's CSO Dr Charles Blundell will give a presentation on 'Quantification of Free Ligand Conformational Preferences by NMR and Their Relationship to the Bioactive Conformation'.

C4X Discovery has applied its technology across a wide range of ligands (small molecule drugs, peptides, macrocycles and cofactors), showing that free solution-structures can be used to accurately predict the bioactive, or 'bound', conformation when bound to their target proteins. Moreover, by measuring the behaviour of ligands in solution, C4XD can understand the dynamics of binding in a way that is unavailable from the static, single-conformation view provided by X-ray co-crystallography, providing a complementary tool for rational drug design. For targets that are not amenable to co-crystallography - which include many important GPCRs and ion channels - C4XD's technology provides a new means of driving the medicinal chemistry design cycle.